News
PRNAF
0.350
NaN%
--
Alterity Therapeutics seeks ASX quotation for new ordinary shares
TipRanks · 12h ago
Alterity Discloses Regal Funds’ Derivative Positions Under Takeovers Panel Guidance
TipRanks · 4d ago
Canaccord Genuity Sticks to Their Buy Rating for Alterity Therapeutics (PRNAF)
TipRanks · 08/13 23:35
Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434
Barchart · 08/12 06:05
Craig-Hallum bullish on Alterity Therapeutics, initiates with a Buy
TipRanks · 08/11 13:11
Alterity Therapeutics initiated with a Buy at Craig-Hallum
TipRanks · 08/11 11:25
Alterity Therapeutics Expands Equity Base With New ASX Share Quotation
TipRanks · 08/10 08:17
Alterity Therapeutics to Highlight MSA Program at Canaccord Growth Conference
TipRanks · 08/06 00:19
Athene Prices $1,000,000,000 Investment Grade Senior Notes Offering
Barchart · 08/05 19:13
Athene Holding Ltd. Declares Third Quarter 2026 Preferred Stock Dividends
Barchart · 08/03 15:30
Alterity Therapeutics Adds 81,838 New Shares to ASX Listing
TipRanks · 08/03 06:46
Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update
Barchart · 07/30 06:25
Alterity Wins FDA Backing for ATH434 Phase 3 Pathway in Multiple System Atrophy
TipRanks · 07/30 00:30
Alterity Options Near Expiry as Company Flags Potential Capital Impact
TipRanks · 07/28 23:57
Alterity Therapeutics Seeks ASX Quotation for New Share Issuance
TipRanks · 07/28 01:07
Athene Announces Second Quarter 2026 Fixed Income Investor Call
Barchart · 07/27 15:30
Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026
Barchart · 07/21 06:25
Alterity Bolsters Cash Reserves with A$3.98m R&D Tax Refund
TipRanks · 07/09 06:03
Alterity Therapeutics Seeks ASX Quotation for New Ordinary Shares
TipRanks · 07/09 01:52
Alterity Therapeutics initiated with a Buy at JonesResearch
TipRanks · 06/29 20:30
More
Webull provides a variety of real-time PRNAF stock news. You can receive the latest news about Alterity Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About PRNAF
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The Company is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.